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Abstract

This paper explores the evolution of the conceptualization of schizophrenia. Specifically, the paper focuses
upon negative symptomology and the emphasis that such symptoms have garnered over time. Negative
symptoms are associated with higher levels of impairment and poorer outcomes in schizophrenia. Historically,
negative symptoms were the core feature of schizophrenia in the early conceptualizations of Kraepelin and
Bleuler, holding precedence until the emergence of Schneiderian theory in the 1970's. The focus on negative
symptoms then changed to positive symptoms; which is still the key focus today. This shift in emphasis has
resulted in a dearth of knowledge and treatment for such symptoms and as such an area requiring further
research. The paper also addresses the conceptual changes in the nosology of Schizophrenia and other
psychosis with respect to the Diagnostic and Statistical Manual of Mental Disorders-5. Further the potential
for the clinical assessment interview for negative symptoms to facilitate understanding and treatments for
negative symptomology in schizophrenia is also discussed.
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Negative symptoms of schizophrenia: A historical,
contemporary, and futuristic view
Shae-Leigh Cynthia Vella, Nagesh B. Pai
Graduate School of Medicine, University of Wollongong, New South Wales, Australia

ABSTRACT
This paper explores the evolution of the conceptualization of schizophrenia. Specifically, the paper focuses upon negative
symptomology and the emphasis that such symptoms have garnered over time. Negative symptoms are associated with higher levels
of impairment and poorer outcomes in schizophrenia. Historically, negative symptoms were the core feature of schizophrenia in the
early conceptualizations of Kraepelin and Bleuler, holding precedence until the emergence of Schneiderian theory in the 1970’s. The
focus on negative symptoms then changed to positive symptoms; which is still the key focus today. This shift in emphasis has resulted
in a dearth of knowledge and treatment for such symptoms and as such an area requiring further research. The paper also addresses
the conceptual changes in the nosology of Schizophrenia and other psychosis with respect to the Diagnostic and Statistical Manual
of Mental Disorders-5. Further the potential for the clinical assessment interview for negative symptoms to facilitate understanding
and treatments for negative symptomology in schizophrenia is also discussed.
Key Words: Diagnostic and Statistical Manual of Mental Disorders-5, Diagnostic and Statistical Manual of Mental Disorders-IV-Text
Revision, history, negative symptoms, schizophrenia

Introduction
Schizophrenia is a chronic and debilitating condition with
the frequently reported prevalence rate of 1% or 1 in 100
individuals being affected, internationally.[1-3] Schizophrenia
is a devastating condition for those that are afflicted as
well as their families and friends. Further schizophrenia,
also exacts a tremendous toll upon society, economically
through service utilization, and lost productivity.[4] As well
as impacting upon societal outcomes such as violence,
substance misuse, homelessness, and suicide within the
community.[5]
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Schizophrenia is a complex condition having a multiplicity
of symptoms that impact upon the core of an individual’s
being; affecting their cognition, emotions, and behaviors.[6,7]
That is, individuals with schizophrenia may have problems
perceiving what is real from what is not real (delusions and
hallucinations). They may behave in a bizarre manner ranging
from childlike behavior to unprovoked agitation (disorganized
behavior). They could completely lack any motivation for
pursing any goal-directed activities (avolition). Further, they
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may have problems with emotional expression, with an
inability to express emotion (affective flattening or blunted
affect) or the expression of contextually inappropriate
emotions (inappropriate affect).
Although schizophrenia has been a focus of scientific
investigation for more than a century,[8,9] a dearth of
knowledge regarding the structure, nosology, and treatment
of the disorder pervades.[10] This scarcity of knowledge
is especially prevalent in regards to the symptoms that
reflect a diminution of normal functioning termed negative
symptoms.[11,12] Approximately, 28-36% of individuals with
schizophrenia comprise a latent group of individuals who
experience severe and enduring negative symptoms.[13]
Arango and Carpenter[14] ascertain that the most common
negative symptoms are alogia, affective flattening (blunted
affect), anhedonia, asociality, avolition, and apathy. Alogia is
defined as a poverty of speech either in frequency or content.
Affective flattening or blunted affect refers to a diminution of
emotional expression. Anhedonia pertains to the inability to
experience pleasure while asociality refers to a general lack
of interest in social relationships. Avolition is defined as a
general lack of motivation, and apathy pertains to a lack of
interest in general.[14]
The presence of negative symptoms in schizophrenia has
consistently been found to result in greater functional
impairment and poorer illness outcomes for those that are
afflicted.[15-17] Further, there are no psychopharmaceutical
agents despite the multitude of them or psychosocial
interventions that effectively treat negative symptomology.[6,18]
Even though the dearth of knowledge and the impact of
negative symptoms are clear; the focus on negative symptoms
in schizophrenia has varied significantly over time. This article
aims to trace the theorizing pertaining to negative symptoms
in schizophrenia over time. Specifically, this article will review
historical and contemporary conceptualizations of schizophrenia
with a focus on the inherent importance of negative symptoms
in the nomenclature of schizophrenia. The recent nomenclature
of negative symptomology in schizophrenia specifically in the
Diagnostic and Statistical Manual of Mental Disorders (DSM)-5
and the clinical assessment interview for negative symptoms
(CAINS) will be discussed with a focus on the potential impact
on the understanding and treatment of negative symptomology
in schizophrenia.

pharaonic Egypt; predating the birth of Christ.[6] The first
conceptual framework of a schizophrenia-like condition
was described by Kraepelin in 1887.[6,9] Kraepelin[9] termed
this condition dementia praecox and postulated that
the condition was marked by reduced cognitive activity,
diminished interest, and lethargy. Further, Kraepelin[9] viewed
schizophrenia (dementia praecox) as a distinct singular
disease entity.
Following Kraepelin, Bleuler[8] further theorized about the
condition known as dementia praecox, which he renamed
as schizophrenia in 1911. Bleuler [8] conceptualized
schizophrenia as a group of disorders as oppose to a
singular disease entity due to the heterogeneity of symptoms
evident in different individuals. Bleuler[8] further outlined
the nosology of schizophrenia, delineating the core of the
disorder; the fundamental symptoms that he believed were
pathognomonic to schizophrenia. In addition, Bleuler[8] also
described a secondary set of symptoms, that is, symptoms
that he believed were not unique to schizophrenia but
were also apparent in other disorders. That is, Bleuler[8]
ascertained that schizophrenia was a disturbance of
association, affectivity, attention, and volition.
Kraepelin[9] and Bleuler’s[8] conception of schizophrenia
differed through their preferred mode of defining the
disorder with; Kraepelin’s[9] definition being based on an
epidemiological stance and Bleuler[8] favoring a nosological
account of schizophrenia.[10,19] Conceptually, their definitions
of the disorder were highly congruent.[8,9] Both Kraepelin[9]
and Bleuler’s[8] notion of schizophrenia emphasized the
loss or diminution of cognitive, affective, and volitional
capacities. Hence, both eminent theorists of schizophrenia
conceptualized the core of schizophrenia to be negative
symptomology.

The Past Nosology of Schizophrenia

This view of schizophrenia remained the prominent
view until the 1960’s when the emphasis shifted
toward symptoms reflective of a disturbance of reality
such as delusions and hallucinations. [6,20] Hence, the
conceptualization of schizophrenia changed to focus on
positive symptomology. This shift in focus occurred for
a number of related reasons namely one primary reason
pertained to improving the reliability of the diagnosis
of the disorder.[6] As positive symptoms reflective of a
reality disturbance are much more easily identifiable being
either present or absent, as oppose to the diminution
of functioning apparent in the negative symptomology
described by Kraepelin[9] and Bleuler.[8]

Accounts of psychotic conditions akin to schizophrenia
spectrum disorders are evident in literature as far back as

Further stimulating this change in the conceptualization
of the core of schizophrenia was the development and
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utilization of the first antipsychotic, chlorpromazine [21]
coupled with the emergence of Schneiderian theory.[22]
Specifically, chlorpromazine, akin to most antipsychotics
(especially the first generation antipsychotics), was effective
in the treatment of positive symptoms associated with
reality disturbances or an excess of functioning as oppose to
symptoms reflective of a diminution of “normal” functional
capacities or negative symptoms.
Schneider [22] proposed 11 first-rank symptoms of
schizophrenia; however, Schneider’s [22] view differed
significantly from that of Kraepelin[9] and Bleuler’s [8]
conception. Although akin to Bleuler, [8] Schneider [22]
believed the symptoms he described were pathognomonic
to schizophrenia. The 11 first-rank symptoms described
by Schneider[22] pertained to disturbances of reality and
perception being much more easily identifiable than
symptoms pertaining to a diminution of functioning. This
significantly changed the symptomology that were viewed
as pathognomonic to schizophrenia. This shift was accepted
with alacrity and quickly became the favored nomenclature
of schizophrenia.[6,19,23,24]
A few theorists continued to recognize the importance of
negative symptomology.[25,26] With Andreasen[27] recognizing
that although positive symptomology is readily identifiable, it
is not the most fundamental characteristic of schizophrenia;
hence, she developed the first scale for measuring negative
symptomology in schizophrenia in 1983; the scale for
the assessment of negative symptoms (SANS). This
instrument offered the first operational definition of the
negative symptomology construct.[27] The SANS measures
the following negative symptoms: Alogia, affective blunting,
avolition — apathy, anhedonia — asociality, and attentional
impairment.[27] Attentional impairment is no longer viewed as
a negative symptom of schizophrenia rather it is recognized
as a cognitive symptom of schizophrenia, although negative
symptoms and cognitive symptoms have been demonstrated
to be related.[28]
Crow [25] defined two types of schizophrenia; Type I
being associated with positive symptoms and Type II
being associated with negative symptoms. Although the
aforementioned types are not intended to be synonymous
with positive and negative symptoms as they are based on
a series of characteristics and not solely the predominance
of positive and negative symptoms.[25,26] Crow[25] proposed
the two dimensions of pathology in schizophrenia, one
dimension being potentially amenable to treatment and
the other associated with a deficit state, the latter being
unchangeable by treatment and associated with poor longterm outcomes.

Furthermore within this period, Carpenter et al. delineated
the distinction between primary (or enduring) and secondary
(nonenduring) negative symptoms. That is, enduring or
deficit negative symptoms were postulated to result from
the clinical core of schizophrenia.[26] Whereas secondary or
nonenduring negative symptoms result from other influences
such as positive symptoms, antipsychotic treatment,
depression, and social deprivation and are generally more
amenable to treatment.[26] Furthermore during this period,
Kay et al.[29] developed the positive and negative syndrome
scale to assess both positive and negative symptomology
along with general psychopathology.
Although some theorists remained interested in negative
symptomology, the primary focus upon a disturbance
of reality and perception as the fundamental basis of
schizophrenia has largely continued until today.[14] With the
pervasiveness of this view, further reflected by the omission
of negative symptoms associated with a diminution of
“normal” functional capacities’ from classificatory systems
until the DSM-IV.[14,30] Such a focus significantly impeded the
development of knowledge pertaining to negative symptoms
and, consequentially, has impacted on the development of
treatments for the aforementioned symptomology.

The Present and Future Nosology
of Schizophrenia
The DSM-IV-Text Revision (TR)[31] defines schizophrenia as
a “disorder that lasts for at least 6 months and includes at
least 1-month of active-phase symptoms (i.e., two or more
of the following: Delusions, hallucinations, disorganized
speech, grossly disorganized or catatonic behavior, negative
symptoms).” Further, the DSM-IV-TR[31] also stipulates that
these symptoms cause discernible social and occupational
dysfunction.
The DSM-IV-TR[31] does incorporate the existence of negative
symptoms into the classification of schizophrenia spectrum
disorders with the DSM-IV-TR[31] including affective flattening,
alogia, and avolition as negative symptoms. Anhedonia
commonly recognized as a negative symptom is merely
classified as an associated feature of schizophrenia in the
DSM-IV-TR.[14,31] Further others[14] ascertain that in addition
to the negative symptoms outlined in the DSM-IV-TR[31]
asociality and apathy are also generally accepted as negative
symptoms of schizophrenia and thus should be included
as such.
The DSM-IV-TR[31] and the ICD-10[32] are comparable in the
diagnosis of schizophrenia with; both making reference
to negative symptomology and requiring the presence of
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delusions and hallucinations for a diagnosis of schizophrenia.
However, although both systems require 1-month of
active-phase symptoms the ICD-10[32] only requires 1-month
of symptoms in total for the diagnosis of schizophrenia in
comparison to the DSM-IV-TR[31] that requires a 6 months
duration of symptoms. Differentially, the ICD-10[32] places
greater emphasis on Schneiderian first-rank symptoms
and has a more detailed complex list of the symptoms of
schizophrenia than the DSM-IV-TR.[31] However, the ICD-10[32]
also places a greater emphasis upon negative symptomology
as well; including a subtype of simple schizophrenia a purely
negative variant of schizophrenia.[20]
Therefore, it is apparent that even though the study of negative
symptoms has come back into favor in recent times[33,34] the
study of the construct remains constrained by the most
widely utilized classificatory system; the DSM-IV-TR.[35] With
symptoms that were historically conceptualized as the core
of schizophrenia; negative symptoms set aside in favor of
a Schneiderian view of the schizophrenia spectrum.[36,37]
Further, the nomenclature delineated in the DSM-IV-TR only
captures a small subset of the clinical core of schizophrenia
due to the stipulated severity (high) required of both
primary negative and disorganized symptoms.[37] Parnas[37]
asserts that this delineation impacts upon the diagnosis of
nonparanoid schizophrenia cases.
In addition to the aforementioned issues with the nosology
of schizophrenia as operationalized in the DSM-IV-TR, there
are many who advocate that schizophrenia as characterized
by enduring primarily negative symptoms is a distinct
separate syndrome.[34,36] Being clinically distinguishable
through several features including; distinct neuroanatomical
features, asocial developmental pattern, reduced substance
use, reduced depression and suicide. [36] Further, the
dimensionality of psychopathology and negative symptoms,
in particular, has also been highlighted.[34]
The DSM-IV-TR has now been superseded by the completion
of the DSM-5.[38] Tandon and Carpenter[39] ascertain that
there were only to be minor changes to the schizophrenia
and other psychotic disorders nomenclature between the
DSM-IV-TR and the DSM-5 however, the changes outlined
may assist with overcoming some of the shortcomings of the
predecessor classificatory system. Further Tandon et al.[40]
ascertain that the DSM-IV definition of schizophrenia is
retained in the DSM-5, however, there is further clarification
of negative symptomology included in the DSM-5.
Significantly Schneiderian first-rank symptoms of
schizophrenia are likely to receive less importance in the
diagnosis of schizophrenia, although there was no mention
332

of placing more emphasis on negative symptomology.[39]
Further, there are no plans to expand the specific symptoms
under the negative symptom construct to reflect all the
symptoms that are commonly conceptualized as a negative
symptom of schizophrenia.[14,39] Rather the terms diminished
emotional expression, and avolition are utilized to capture
the negative symptomology construct, along with alogia,
anhedonia, and asociality.[38]
Further the traditional subtypes of schizophrenia
(disorganized, paranoid, and catatonic) have been
abandoned to reflect the fact that most people with
schizophrenia have the symptomology associated with
multiple subtypes of schizophrenia and move through the
different subtypes over the duration of their illness.[40] Rather
the heterogeneity of schizophrenia will be characterized by
the incorporation of dimensional ratings of the different
psychopathological domains of schizophrenia and psychotic
spectrum disorders.[38,39] Each of the psychopathological
domains is rated on a scale from 0; not present through
to 4; severe.[38] This abandonment of the traditional subtypes
and the acceptance of a dimensional approach may increase
the heuristic value and clinical utility of the nosology. As
the adoption of a dimensional approach aligns to reflect
the heterogeneity of schizophrenia; thus increasing the
pragmatic value of the diagnosis for both research and
clinical practice alike.[21] Such an approach will also reduce
the heterogeneity that is apparent in the traditional subtypes
of schizophrenia.[41] Further, this approach to the diagnosis
of schizophrenia has particular significance in regards to
functional assessment. However, others have contended
that the key strength of the DSM-IV criteria is its clinical
utility and as such the DSM-5 should be even more superior
for clinical usage,[35] through time and use it should become
apparent whether the DSM-5 has increased clinical utility. In
contrast, they also ascertain that the DSM continues to limit
understanding and research into the schizophrenia construct
through the atheoretical diagnostic criteria espoused.[35]
It still remains that more emphasis needs to be placed
upon negative symptomology with the conceptual domains
and relationships between the specific symptoms clearly
delineated. Recently, the National Institute of Mental Health
(NIMH) - measurement and treatment research to improve
cognition in schizophrenia (MATRICS) released a consensus
statement highlighting recommendations to assist with
the development of treatments for negative symptoms in
schizophrenia.[42] It is only with a clearer conceptualization
as well as placing more importance upon these symptoms
that advances can be made. However, Tarrier[43] noted
that the NIMH-MATRICS consensus statement was biased
toward the neurobiological mechanisms that underpin
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negative symptomology and thus the development of
psychopharmaceutical agents to the exclusion of psychosocial
interventions. In addition, Tarrier[43] ascertained that further
delineation and focus on the conceptual basis of negative
symptomology would be beneficial in the development of
both psychopharmaceutical and psychosocial treatments
for negative symptoms in schizophrenia.
Recently, the collaboration to advance negative symptom
assessment of schizophrenia (CANSAS) was established
to develop a clinical assessment scale for negative
symptomology in schizophrenia.[33,44,45] This working group
has developed and commenced validating a measure
for the clinical assessment of schizophrenia namely;
the CAINS.[33,44,45] The CAINS was specifically designed
to overcome the limitations inherent in the existing
instruments.[45] Further, the development of the CAINS aims
to promote innovative research into treatments for negative
symptoms both pharmacological and psychosocial.[45]
Along with advancing understanding pertaining to the
underlying causes of schizophrenia as well as assisting
with endeavors to forge and unite neuroscience based
accounts of schizophrenia with other clinical and theoretical
descriptions of schizophrenia.[45]
The CAINS offers immense hope to the assessment and
treatment of negative symptomology in the future. Through
a unique development and validation process the CANSAS
has conducted initial validation of the CAINS, with the
CAINS incorporating five core negative symptoms, namely
asociality, avolition, anhedonia (both consummatory and
anticipatory), blunted affect and alogia.[45] Initial validation
procedures have demonstrated a two-factor model pertaining
to experiential and expressive negative symptoms.[45]
It is hoped that the changes evident in the DSM-5
schizophrenia criteria although only indirectly linked
to negative symptomology, through less reliance upon
Schneiderian first-rank symptoms of schizophrenia will
increase awareness of negative symptomology. Similarly it
is anticipated that the new instrument for the assessment of
negative symptoms; the CAINS will promote the significance
of the negative symptomology in schizophrenia and the
necessity for a greater understanding of the construct,
along with the development of effective treatments for such
debilitating symptoms. Further, it is also hoped that the
aforementioned changes that have the potential to facilitate
a greater understanding of negative symptomology are also
apparent in the forthcoming ICD-11.
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